Ether à go-go 1 silencing in combination with TRAIL overexpression has synergistic antitumor effects on osteosarcoma

Area of Science:

• Oncology
• Gene Therapy
• Molecular Biology

Background:

• Cancer cell resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) therapy is a significant challenge.
• Ether à go-go 1 (Eag1) channel overexpression is linked to various cancer progressions, but its therapeutic role in osteosarcoma is unexplored.

Purpose of the Study:

• To investigate the antitumor efficacy of a novel adenoviral vector, CRAd5.TRAIL/siEag1, designed for simultaneous Eag1 knockdown and TRAIL overexpression.
• To evaluate the vector's effects on human osteosarcoma MG-63 cells and an osteosarcoma xenograft model.

Main Methods:

• Generation of a dual-action adenoviral vector (CRAd5.TRAIL/siEag1) for combined Eag1 silencing and TRAIL upregulation.
• In vitro assessment of the vector's impact on MG-63 osteosarcoma cells and hFOB 1.19 normal osteoblasts.
• In vivo evaluation using an osteosarcoma xenograft mouse model.

Main Results:

• CRAd5.TRAIL/siEag1 significantly induced growth arrest and apoptosis in MG-63 cells, surpassing individual gene treatments.
• The vector demonstrated specificity, with no adverse effects observed on normal human osteoblastic hFOB 1.19 cells.
• In vivo studies showed marked tumor regression and enhanced cancer cell apoptosis in the CRAd5.TRAIL/siEag1 treated xenograft model.

Conclusions:

• The combined Eag1 knockdown and TRAIL overexpression strategy via CRAd5.TRAIL/siEag1 exhibits synergistic antitumor effects.
• This dual-targeting adenoviral vector presents a promising and effective gene therapy approach for osteosarcoma treatment.